( NASDAQ-SMALL:XTLB,TelAviv:XTLB )

News from XTL Biopharmaceuticals Ltd A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Jan 05, 2017, 08:30 ET XTL Biopharmaceuticals' Preclinical Studies of hCDR1 Demonstrate Therapeutic Potental In the Treatment of Sjögren's Syndrome

XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing...


Dec 19, 2016, 08:00 ET XTL Biopharmaceuticals to Present at Biotech Showcase

XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing its lead...


Dec 06, 2016, 08:30 ET XTL Biopharmaceuticals Reports Third Quarter 2016 Financial Results & Provides Clinical and Operational Update

XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing its lead...


Nov 09, 2016, 13:25 ET XTL Biopharmaceuticals Receives NASDAQ Notification Regarding Minimum Bid Requirements

XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing its lead...


Sep 27, 2016, 08:30 ET XTL Biopharmaceuticals Reports Second Quarter 2016 Financial Results & Provides Clinical and Operational Update

 XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing its...


Sep 07, 2016, 08:32 ET XTL Biopharmaceuticals Announces the European Patent Office has Issued a Patent for its Lupus Drug hCDR1

XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing its lead...


Sep 06, 2016, 08:00 ET XTL Biopharmaceuticals to Present at Rodman & Renshaw Conference on September 12, 2016

XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing its lead...


Aug 11, 2016, 09:00 ET XTL Biopharmaceuticals Announces New Patent Filing in U.S. for Lupus Drug hCDR1

XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing its lead...


Jun 01, 2016, 08:30 ET XTL Biopharmaceuticals Reports First Quarter 2016 Financial Results & Provides Clinical and Operational Update

 XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing...


Mar 21, 2016, 08:30 ET XTL Biopharmaceuticals Completes Phase 2 Trial Design for Lead Compound hCDR1 in the Treatment of Lupus

XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing its lead...


Mar 09, 2016, 08:29 ET Lupus Thought Leader Daphna Paran, MD, Named Medical Director of XTL Biopharmaceuticals

XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing its lead...


Feb 22, 2016, 09:02 ET XTL Biopharmaceuticals Receives European Medicines Agency's SME Status

XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing its lead...


Feb 10, 2016, 08:30 ET XTL Biopharmaceuticals' Lupus Drug hCDR1 Granted Patent for Pharmaceutical Composition & Manufacturing Processes

XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing its lead...


Jan 27, 2016, 08:30 ET XTL Biopharmaceuticals Joins Corporate Advisory Council of the Lupus Foundation of America

XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing its lead...


Jan 25, 2016, 08:30 ET XTL Biopharmaceuticals Announces Encouraging Feedback from U.S. FDA on its Upcoming IND Filing for Lupus Drug hCDR1

XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing its lead...


Jan 13, 2016, 08:30 ET XTL Biopharmaceuticals Advances Formulation of its hCDR1 Drug for Clinical Trials in the Treatment of Lupus Through use of Cydex Pharmaceuticals' Captisol®

XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing its lead...


Jan 11, 2016, 08:30 ET XTL Biopharmaceuticals Submits Protocol to Yeda for Advanced Clinical Trial of hCDR1 in the Treatment of Lupus

XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing its lead...


Dec 01, 2015, 08:30 ET XTL Biopharmaceuticals Reports Third Quarter 2015 Results and Confirms Intention to Start Lupus Trial In 2016

 XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company focused on the...


Oct 28, 2015, 09:00 ET Dr. Murray Urowitz, of the University of Toronto University Health Network, Provides Overview of an Analysis of Data from a Phase II Clinical Study of hCDR1 (Edratide) for the Treatment of Lupus

XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company focused on the...


Oct 26, 2015, 09:15 ET XTL Biopharmaceuticals to Present at BIO-Europe 2015 in Munich, Germany on November 3rd, 2015

XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company focused on the...


Oct 13, 2015, 08:45 ET XTL Biopharmaceuticals Announces Agreement With Yeda Research and Development Company Ltd. to Amend License Agreement for Lupus Asset

XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company focused on the...


Sep 03, 2015, 09:00 ET XTL Biopharmaceuticals to Present at the Rodman & Renshaw 17th Annual Global Investment Conference on September 10th 2015 at the St. Regis Hotel in NYC

XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company focused on the...


Sep 01, 2015, 09:00 ET XTL Biopharmaceuticals Reports Second Quarter 2015 Results

 XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company focused on the...


Feb 17, 2015, 08:30 ET Biotech Investor Alex Rabinovich Increases Stake in XTL Biopharmaceuticals

 XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB) (TASE: XTL) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company focused on the...


Dec 30, 2014, 12:23 ET XTL Biopharmaceuticals Annual General Meeting of Shareholders Appoints Two New Members to the Board of Directors

 XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company focused on the...